U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07310784) titled 'A Phase II Trial of LM103 in Advanced Melanoma' on Dec. 16.
Brief Summary: A total of 92 subjects with advanced melanoma who met the inclusion criteria will be randomly assigned in a 1:1 ratio to the experimental group and the control group in this phase II trial. The study will be followed up until 24 months after treatment.
Study Start Date: Dec. 16
Study Type: INTERVENTIONAL
Condition:
Advanced Melanoma
Intervention:
BIOLOGICAL: LM103 TILs Injection
Extract, culture and expand tumor-infiltrating lymphocytes from resected tumor tissues in vitro for the manufactur of LM103 TILs injection. After NMA-LD, the subjects received ...